BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jul 11, 2011
 |  BioCentury  |  Product Development

Supplanting by implanting

Intarcia hopes implanted exenatide can compete with oral therapies in diabetes

GLP-1 agonists provide comparable or better HbA1c reductions than the more popular DPP-4 inhibitors and have the added benefit of weight loss in Type II diabetes. But GLP-1 agonists are less widely used because they must be subcutaneously injected and have a relatively high rate of side effects, most notably nausea.

Intarcia Therapeutics Inc. believes its ITCA 650 solves both problems. In June, the company presented 48-week Phase II data at the American Diabetes Association meeting in San Diego suggesting the implantable exenatide delivery system could match or beat injectable GLP-1 receptor agonists on safety and efficacy.

Based on these results, the company thinks the product also is well positioned to compete with oral therapies. By year end, Intarcia hopes to announce a partner and start the first of three Phase III trials designed to show the superiority of its product to dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas.

ITCA 650 contains a stabilized formulation of exenatide in a Duros osmotic mini-pump. The device is implanted under abdominal skin during a routine doctor's visit, and can deliver a standardized dose of exenatide for up to a year.

The protein stabilizing formulation was developed at...

Read the full 971 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >